Litcius/Paper detail

Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma

Masatoshi Kudo

2022Liver Cancer84 citationsDOIOpen Access PDF

Abstract

N/A

Topics & Concepts

AtezolizumabBevacizumabMedicineHepatocellular carcinomaStage (stratigraphy)OncologyInternal medicineCancerChemotherapyImmunotherapyPembrolizumabBiologyPaleontologyHepatocellular Carcinoma Treatment and PrognosisColorectal Cancer Treatments and StudiesCancer, Hypoxia, and Metabolism